Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals is positioned for durable long-term growth because its TTR franchise remains the core value driver, with AMVUTTRA as the only ATTR therapy labeled across the full patient spectrum and nucresiran offering a next-generation, more margin-accretive follow-on. The company’s outlook is further supported by a large, underpenetrated ATTR-CM market—about 200,000 U.S. patients and 500,000 globally, with most untreated—plus management’s expectation for continued prescription growth and franchise revenues exceeding $20.5 billion by 2040. Beyond TTR, zilebesiran, ALN-6400, and other pipeline assets add meaningful optionality, while recent clinical readouts and partner progress reinforce the platform’s broad therapeutic reach and de-risk the RNAi mechanism.

Alnylam Pharmaceuticals is facing a cautious outlook because, despite encouraging biomarker data for zilebesiran, the program still has meaningful uncertainty around event-driven efficacy, prespecified endpoints, and whether the UACR signal truly translates into a renal composite benefit. Safety appears manageable across 889 exposed patients, but confirmed hyperkalemia of 2.7% versus 0.9% on placebo, plus unanswered questions on REVERSIR and potassium screening, leave material clinical and execution risk in a six-month-duration therapy. Valuation is also pressured by a heavy risk stack, including 50% success assumptions for zilebesiran and elebsiran, 15% for ALN-HSD, and subpoena-related expense that could hurt gross-to-net and future profitability assumptions.